

PHILIP MORRIS INTERNATIONAL

## PRESS RELEASE

Investor Relations: Stamford, CT: +1 (203) 904 2410 Lausanne: +41 (0)58 242 4666 Email: InvestorRelations@pmi.com Media: David Fraser Lausanne: +41 (0)58 242 4500 Email: David.Fraser@pmi.com

## PHILIP MORRIS INTERNATIONAL TO HOST WEBCAST OF PRESENTATION AT THE 2023 DEUTSCHE BANK GLOBAL CONSUMER CONFERENCE

STAMFORD, CONNECTICUT – May 30, 2023 – Philip Morris International Inc. (PMI) (NYSE: PM) will host a live webcast of the company's remarks and Q&A session with Emmanuel Babeau, Chief Financial Officer, at the 2023 Deutsche Bank Global Consumer Conference at <u>www.pmi.com/2023deutschebank</u> on Tuesday, June 6, 2023, at approximately 9:15 a.m. CET (3:15 a.m. ET).

The webcast will provide a live stream of the entire PMI session. The webcast may also be accessed on mobile devices by downloading PMI's free Investor Relations Mobile App at <a href="http://www.pmi.com/irapp">www.pmi.com/irapp</a>.

The presentation slides will be available at <u>www.pmi.com/2023deutschebank</u>. An archived copy of the webcast will be available until 5:00 p.m. ET on Friday, July 7, 2023, at the same site.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies' *IQOS* and *ZYN* brands. The U.S. Food and Drug Administration (FDA) has authorized versions of PMI's *IQOS* Platform 1 devices and consumables and Swedish Match's *General* snus as Modified Risk Tobacco Products (MRTPs). As of March 31, 2023, PMI's smoke-free products were available for sale in 78 markets, and PMI estimates that approximately 18.5 million adults around the world had already switched to *IQOS* and stopped smoking. Smoke-free products accounted for approximately 35% of PMI's total 2023 first-quarter net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit <u>www.pmi.com</u> and <u>www.pmiscience.com</u>.